Prospective Grant of Exclusive License: Veterinary Vaccines for Rift Valley Fever Virus, 68783-68784 [2012-27897]

Download as PDF Federal Register / Vol. 77, No. 222 / Friday, November 16, 2012 / Notices Status: Open to the public, limited only by the number of phone lines available. Purpose: The committee provides advice and guidance to the Secretary, HHS; the Assistant Secretary for Health; and the Director, CDC, regarding the formative research, development, implementation and evaluation of evidence-based activities designed to prevent breast cancer (particularly among those at heightened risk) and promote the early detection and support of young women who develop the disease. The advice provided by the Committee will assist in ensuring scientific quality, timeliness, utility, and dissemination of credible appropriate messages and resource materials. Matters To Be Discussed: The agenda will include discussions on approaches to increase awareness of clinicians/practitioners regarding topics such as breast health, symptoms, diagnosis, and treatment of breast cancer in young women; and information needs and delivery mechanisms for women at higher risks for developing breast cancer. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Temeika L. Fairley, Ph.D., Designated Federal Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 5770 Buford Hwy, NE., Mailstop K52, Atlanta, Georgia 30341, Telephone (770) 488–4518, Fax (770) 488–4760, Email: acbcyw@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention, and Agency for Toxic Substances and Disease Registry. Dated: November 8, 2012. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2012–27901 Filed 11–15–12; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Prospective Grant of Co-Exclusive License: Veterinary Vaccines for Rift Valley Fever Virus Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice. mstockstill on DSK4VPTVN1PROD with NOTICES AGENCY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS), is thinking about giving SUMMARY: VerDate Mar<15>2010 15:43 Nov 15, 2012 Jkt 229001 a co-exclusive license in Africa, in the field of use of veterinary vaccines, to practice the inventions listed in the patent applications referred to below to Deltamune Ltd., having a place of business in Centurion, South Africa. The patent rights in these inventions have been assigned to the government of the United States of America. The patent applications(s) to be licensed are: US Provisional Application 61/016,065, filed 12/21/2007, entitled ‘‘Development of Rift Valley Fever Virus Utilizing Reverse Genetics,’’ US Provisional Application 61/ 042,987, filed 4/7/2008, entitled ‘‘Recombinant Rift Valley Fever (RVF) Viruses and Method of Use,’’ PCT Application PCT/US2008/087023, filed 12/ 16/2008, entitled ‘‘Recombinant Rift Valley Fever (RVF) Viruses and Method of Use,’’ US National Stage Application 12/809,561, filed 6/18/2010, entitled ‘‘Recombinant Rift Valley Fever (RVF) Viruses and Methods of Use,’’ and all related continuing and foreign patents/patent applications for the technology family. CDC Technology ID No. I– 008–08. Status: Pending. Priority Date(s): 61/042,987: 4/7/2008 61/016,065: 12/21/2007 The planned co-exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. Technology: The technology allows for the generation of precisely defined attenuated vaccine constructs that contain complete deletions of critical virulence factors of Rift Valley Fever (RVF) virus. These attenuated vaccines constructs still have the ability to induce robust protective immunity following the administration of a single vaccine dose in a rat model of lethal disease. The vaccines can protect immunized animals against virulent virus challenge. The vaccine candidates also allow for the differentiation of naturally infected and vaccinated animals—a feature that is critical in agricultural settings. This approach will allow for the rapid generation of effective, safe RVF vaccine candidates to control and prevent the spread of wildtype RVF virus in a variety of settings, including preventing the infection of humans or animals during endemic, epidemic or epizootic situations in affected countries, or for prophylactic use among humans in high risk occupational settings, or following intentional release of RVF virus during bioterrorism. DATES: Only written comments and/or applications for a license which are received by CDC on or before December 17, 2012 will be considered. PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 68783 Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the planned license should be directed to Donald Prather, J.D., Ph.D., Technology Licensing and Marketing Specialist, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K–79, Atlanta, GA 30341, Telephone: (770) 488–8612; Facsimile: (770) 488–8615; Email: dmprather@cdc.gov. SUPPLEMENTARY INFORMATION: Applications for a license filed in response to this notice will be treated as objections to giving the planned license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. ADDRESSES: Dated: November 8, 2012. J. Ronald Campbell, Director, Division of Executive Secretariat, Centers for Disease Control and Prevention. [FR Doc. 2012–27896 Filed 11–15–12; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Prospective Grant of Exclusive License: Veterinary Vaccines for Rift Valley Fever Virus Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice. AGENCY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS), is thinking of giving a co-exclusive license in Africa, and an exclusive license in all territories other than Africa, in the field of use of veterinary vaccines, to practice the inventions listed in the patent applications referred to below to Merial Limited, having a place of business in Duluth, Georgia. The patent rights in these inventions have been assigned to the government of the United States of America. The patent application(s) to be licensed are: SUMMARY: US Provisional Application 61/016,065, filed 12/21/2007, entitled ‘‘Development of Rift Valley Fever Virus Utilizing Reverse Genetics,’’ US Provisional Application 61/ E:\FR\FM\16NON1.SGM 16NON1 68784 Federal Register / Vol. 77, No. 222 / Friday, November 16, 2012 / Notices mstockstill on DSK4VPTVN1PROD with NOTICES 042,987, filed 4/7/2008, entitled ‘‘Recombinant Rift Valley Fever (RVF) Viruses and Method of Use,’’ PCT Application PCT/US2008/087023, filed 12/ 16/2008, entitled ‘‘Recombinant Rift Valley Fever (RVF) Viruses and Method of Use,’’ US National Stage Application 12/809,561, filed 6/18/2010, entitled ‘‘Recombinant Rift Valley Fever (RVF) Viruses and Methods of Use,’’ and all related continuing and foreign patents/patent applications for the technology family. CDC Technology ID No. I– 008–08. Status: Pending. Priority Date(s): 61/042,987 4/7/2008. 61/016,065 12/21/2007. The planned co-exclusive license and exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. Technology: The technology allows for the generation of precisely defined attenuated vaccine constructs that contain complete deletions of critical virulence factors of Rift Valley Fever (RVF) virus. These attenuated vaccines constructs still have the ability to induce robust protective immunity following the administration of a single vaccine dose in a rat model of lethal disease. The vaccines can protect immunized animals against virulent virus challenge. The vaccine candidates also allow for the differentiation of naturally infected and vaccinated animals—a feature that is critical in agricultural settings. This approach will allow for the rapid generation of effective, safe RVF vaccine candidates to control and prevent the spread of wildtype RVF virus in a variety of settings, including preventing the infection of humans or animals during endemic, epidemic or epizootic situations in affected countries, or for prophylactic use among humans in high risk occupational settings, or following intentional release of RVF virus during bioterrorism. DATES: Only written comments and/or applications for a license which are received by CDC on or before December 17, 2012 will be considered. ADDRESSES: Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the planned license should be directed to Donald Prather, J.D., Ph.D., Technology Licensing and Marketing Specialist, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K–79, Atlanta, GA 30341, Telephone: (770) 488–8612; Facsimile: (770) 488–8615; Email: dmprather@cdc.gov. VerDate Mar<15>2010 15:43 Nov 15, 2012 Jkt 229001 SUPPLEMENTARY INFORMATION: Applications for a license filed in response to this notice will be treated as objections to giving the planned license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: November 8, 2012. J. Ronald Campbell, Director, Division of Executive Secretariat, Centers for Disease Control and Prevention. [FR Doc. 2012–27897 Filed 11–15–12; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Prospective Grant of Exclusive License: Multiple-Valent Opsonophagocytic Assay Selection Panel Arrays Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice. AGENCY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS), is thinking about giving a worldwide, exclusive license to practice the inventions listed in the patent referred to below to Flow Applications, Inc., having a place of business in Okawville, Illinois. The patent rights in these inventions have been assigned to the government of the United States of America. The patent to be licensed is: SUMMARY: US Patent 7,642,068, entitled, ‘‘MultipleValent Opsonophagocytic Assay Selection Panel Arrays and Uses Therefor’’, issued 1/ 5/2010. CDC Technology ID No. I–035–04. Status: Patent Issued. Priority Date: 4/22/2005. Issue Date: 1/5/2010. The planned exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. Technology: This technology utilizes a specific medium for the selection of up to 90 different Streptococcus pneumoniae serotypes following a viability opsonophagocytosis assay. This medium includes different antibiotics, growth factors for pneumococcus, and a colorimetric PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 detection agent. These specific antibiotic panels can be preserved for later use in conjunction with a panel of selected pneumococcal strains that will allow for the measurement of functional antibodies elicited by pneumococcal vaccines. DATES: Only written comments and/or applications for a license which are received by CDC on or before December 3, 2012 will be considered. ADDRESSES: Requests for a copy of this patent, inquiries, comments, and other materials relating to the contemplated license should be directed to Donald Prather, J.D., Ph.D., Technology Licensing and Marketing Specialist, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K–79, Atlanta, GA 30341, Telephone: (770) 488–8612; Facsimile: (770) 488–8615: Email: dwj5@cdc.gov. SUPPLEMENTARY INFORMATION: Applications for a license filed in response to this notice will be treated as objections to giving the planned license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: November 8, 2012. J. Ronald Campbell, Director, Division of Executive Secretariat Centers for Disease Control and Prevention. [FR Doc. 2012–27895 Filed 11–15–12; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Standard Test Procedures Approval Process for Respirators To Be Used in Wildland Fire-Fighting Operations; Standard Test Procedures for Composite Multi-Gas and Particulate Protection and Approval Process for Respirators To Be Used in Wildland Fire-Fighting Operations The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Respirators with Composite Protection for Wildland Fire-Fighting Operations; Notice of Testing and Evaluation. AGENCY: The Centers for Disease Control and Prevention’s (CDC) National SUMMARY: E:\FR\FM\16NON1.SGM 16NON1

Agencies

[Federal Register Volume 77, Number 222 (Friday, November 16, 2012)]
[Notices]
[Pages 68783-68784]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-27897]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Veterinary Vaccines for 
Rift Valley Fever Virus

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Technology Transfer Office, Centers for 
Disease Control and Prevention (CDC), Department of Health and Human 
Services (HHS), is thinking of giving a co-exclusive license in Africa, 
and an exclusive license in all territories other than Africa, in the 
field of use of veterinary vaccines, to practice the inventions listed 
in the patent applications referred to below to Merial Limited, having 
a place of business in Duluth, Georgia. The patent rights in these 
inventions have been assigned to the government of the United States of 
America. The patent application(s) to be licensed are:

    US Provisional Application 61/016,065, filed 12/21/2007, 
entitled ``Development of Rift Valley Fever Virus Utilizing Reverse 
Genetics,'' US Provisional Application 61/

[[Page 68784]]

042,987, filed 4/7/2008, entitled ``Recombinant Rift Valley Fever 
(RVF) Viruses and Method of Use,'' PCT Application PCT/US2008/
087023, filed 12/16/2008, entitled ``Recombinant Rift Valley Fever 
(RVF) Viruses and Method of Use,'' US National Stage Application 12/
809,561, filed 6/18/2010, entitled ``Recombinant Rift Valley Fever 
(RVF) Viruses and Methods of Use,'' and all related continuing and 
foreign patents/patent applications for the technology family. CDC 
Technology ID No. I-008-08.

    Status: Pending.
    Priority Date(s):
61/042,987 4/7/2008.
61/016,065 12/21/2007.

    The planned co-exclusive license and exclusive license will be 
royalty-bearing and will comply with the terms and conditions of 35 
U.S.C. 209 and 37 CFR 404.7.
    Technology: The technology allows for the generation of precisely 
defined attenuated vaccine constructs that contain complete deletions 
of critical virulence factors of Rift Valley Fever (RVF) virus. These 
attenuated vaccines constructs still have the ability to induce robust 
protective immunity following the administration of a single vaccine 
dose in a rat model of lethal disease. The vaccines can protect 
immunized animals against virulent virus challenge. The vaccine 
candidates also allow for the differentiation of naturally infected and 
vaccinated animals--a feature that is critical in agricultural 
settings. This approach will allow for the rapid generation of 
effective, safe RVF vaccine candidates to control and prevent the 
spread of wild-type RVF virus in a variety of settings, including 
preventing the infection of humans or animals during endemic, epidemic 
or epizootic situations in affected countries, or for prophylactic use 
among humans in high risk occupational settings, or following 
intentional release of RVF virus during bioterrorism.

DATES: Only written comments and/or applications for a license which 
are received by CDC on or before December 17, 2012 will be considered.

ADDRESSES: Requests for a copy of these patent applications, inquiries, 
comments, and other materials relating to the planned license should be 
directed to Donald Prather, J.D., Ph.D., Technology Licensing and 
Marketing Specialist, Technology Transfer Office, Centers for Disease 
Control and Prevention (CDC), 4770 Buford Highway, Mailstop K-79, 
Atlanta, GA 30341, Telephone: (770) 488-8612; Facsimile: (770) 488-
8615; Email: dmprather@cdc.gov.

SUPPLEMENTARY INFORMATION: Applications for a license filed in response 
to this notice will be treated as objections to giving the planned 
license.
    Comments and objections submitted in response to this notice will 
not be made available for public inspection, and, to the extent 
permitted by law, will not be released under the Freedom of Information 
Act, 5 U.S.C. 552.

    Dated: November 8, 2012.
J. Ronald Campbell,
Director, Division of Executive Secretariat, Centers for Disease 
Control and Prevention.
[FR Doc. 2012-27897 Filed 11-15-12; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.